BMD4503-2

BMD4503-2 is a quinoxaline derivative with inhibitory activity against LRP5/6-sclerostin interactions. BMD4503-2 restores the activity of the Wnt/β-catenin signaling pathway by competitively binding to the LRP5/6-sclerostin complex. BMD4503-2 can be used in the study of Wnt signaling pathways in bone development, maintenance and osteoporosis[1].

Product Specifications

CAS Number

301357-87-9

UNSPSC

12352005

Target

Others

Type

Reference compound

Related Pathways

Others

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/bmd4503-2.html

Purity

99.21

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC(NC1=CC=C(C=C1)S(=O)(NC2=NC3=CC=CC=C3N=C2NC4=C5C=CC=CC5=CC=C4)=O)=O

Molecular Formula

C26H21N5O3S

Molecular Weight

483.54

References & Citations

[1]Choi J, et al. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors[J]. Bioorganic & Medicinal Chemistry Letters, 2018, 28 (6) : 1116-1121.